Ponesimod vs tamuzimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Phase 3 in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2029 · NCT07686081 (registry estimate)

No aligned efficacy figure on record for this race.

tamuzimod

Developed by Eli Lilly and partners

Phase 2 in Ulcerative ColitisSmall molecule (oral S1P1 receptor modulator)
Reliable signal

NCT05156125 · Phase 2 · terminated

This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.

Reported efficacy

Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): VTX002 60 mg Once Daily 19/68 (27.9%) | VTX002 30 mg Once Daily 17/71 (23.9%) vs Placebo Once Daily 8/70 (11.4%) (met)

Result source: NCT05156125

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPonesimodtamuzimod
Clinical remission (induction)—Trial running · NCT0768608127.9% vs 11.4%+16.5 vs placebo60 mg once daily · wk 13 · n 68NCT05156125
1 other result
  • 23.9% vs 11.4% 30 mg once daily · wk 13 · n 71 · Phase 2 · primary NCT05156125
Clinical remission (maintenance)—Trial running · NCT07686081—Not reported
Clinical response (induction)—Trial running · NCT07686081—Not reported
Endoscopic improvement (induction)—Trial running · NCT07686081—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT07686081—Not reported

Clinical remission (induction)

Ponesimod
—Trial running · NCT07686081
tamuzimod
27.9% vs 11.4%+16.5 vs placebo60 mg once daily · wk 13 · n 68NCT05156125
1 other result
  • 23.9% vs 11.4% 30 mg once daily · wk 13 · n 71 · Phase 2 · primary NCT05156125

Clinical remission (maintenance)

Ponesimod
—Trial running · NCT07686081
tamuzimod
—Not reported

Clinical response (induction)

Ponesimod
—Trial running · NCT07686081
tamuzimod
—Not reported

Endoscopic improvement (induction)

Ponesimod
—Trial running · NCT07686081
tamuzimod
—Not reported

Corticosteroid-free remission (maintenance)

Ponesimod
—Trial running · NCT07686081
tamuzimod
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ponesimod: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ponesimod: 0 of 4 rows · tamuzimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictamuzimod
Dropout rate
4.3%60 mg once dailya
NCT05156125 · Phase 2 · monotherapy
show 6 more results
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
4.1%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Discontinued due to AEs
2.9%60 mg once dailya
NCT05156125 · Phase 2 · monotherapy
show 6 more results
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—60 mg once daily
NCT05156125 · Phase 2 · monotherapy
1.4%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Serious AEs
—60 mg once dailya
NCT05156125 · Phase 2 · monotherapy
show 6 more results
4.3%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
0%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
4.2%60 mg once daily
NCT05156125 · Phase 2 · monotherapy
—30 mg once daily
NCT05156125 · Phase 2 · monotherapy
2.7%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
5.4%30 mg once daily
NCT05156125 · Phase 2 · monotherapy
Most frequent reported AEs
60 mg once dailya
upper respiratory tract infection 8.6% (placebo 1.4%)
headache 5.7% (placebo 2.9%)
anaemia 2.9% (placebo 8.6%)
NCT05156125 · Phase 2 · monotherapy
show 4 more results
60 mg once daily
alanine aminotransferase increased 6.1% (placebo 1.4%)
aspartate animotransferase increased 6.1% (placebo 0%)
gamma-glutamyltransferase increased 6.1% (placebo 1.4%)
NCT05156125 · Phase 2 · monotherapy
60 mg once daily
lymphopenia 28.9% (placebo 0%)
nasopharyngitis 7.4% (placebo 4.3%)
upper respiratory tract infection 6.3% (placebo 1.4%)
NCT05156125 · Phase 2 · monotherapy
30 mg once daily
headache 6.8% (placebo 2.9%)
anaemia 5.5% (placebo 8.6%)
lymphopenia 1.4% (placebo 0%)
NCT05156125 · Phase 2 · monotherapy
30 mg once daily
gamma-glutamyltransferase increased 10.8% (placebo 1.4%)
alanine aminotransferase increased 5.4% (placebo 1.4%)
arthralgia 5.4% (placebo 0%)
NCT05156125 · Phase 2 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tamuzimod

Clinical Remission 27.9% (n=68) vs 11.4% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 19 Participants as posted
show 1 more result
23.9% (n=71) vs 11.4% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 17 Participants as posted
Endoscopic Improvement 36.8% (n=68) vs 15.7% (n=70) placebo @ 13wk60 mg once daily
event count · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 25 Participants as posted
show 1 more result
32.4% (n=71) vs 15.7% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 23 Participants as posted
Symptomatic Remission 42.6% (n=68) vs 25.7% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted
show 1 more result
40.8% (n=71) vs 25.7% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted
Histologic Remission 19.1% (n=68) vs 7.1% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 13 Participants as posted
show 1 more result
28.2% (n=71) vs 7.1% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 20 Participants as posted
Endoscopic Improvement-Histologic Remission 10.3% (n=68) vs 0% (n=70) placebo @ 13wk60 mg once daily
responder rate · % of participants
NCT05156125 · Phase 2 · monotherapy · converted to % from 7 Participants as posted
show 1 more result
19.7% (n=71) vs 0% (n=70) placebo @ 13wk*30 mg once daily
NCT05156125 · Phase 2 · monotherapy · converted to % from 14 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponesimod's landscape · tamuzimod's landscape